Quality of life (QoL) in patients on Abilify Maintena in the private setting.

Phase 4

Completed

• Conditions: Schizophrenia; Quality of Life; Mental Health - Schizophrenia

• Registration Number: ACTRN12617000211369
• Lead Sponsor: Dr. Benjamin Hadikusumo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-02-08
• Study Completion: 2018-12-28
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Patients with a formal diagnosis of Schizophrenia as per DSM-V, patients aged between 18 and 65 (inclusive), able to give informed consent.

Exclusion Criteria

Patients who are currently receiving Clozapine, patients with other serious comorbid psychiatric or medical illness, patients who are treatment refractory, patients who are pregnant or breastfeeding, patients who have concomitant use of any other antipsychotic

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Quality of Life (QoL) using a validated assessment tool. <br><br>The primary QOL outcome is the change in quality of life as assessed by the Quality of Life Scale (QLS).[6 months post stabilisation period. <br>Upon enrolment, patients start a 3-month stabilisation period, prior to the study period of 6 months.]

Secondary Outcome Measures

Name	Time	Method
The change in quality of life as assessed by the World Health Organisation Quality of Life (WHOQOL-BREF) [6 months post stabilisation period. <br>Upon enrolment, patients start a 3-month stabilisation period, prior to the study period of 6 months.];The change in quality of life as assessed by the Clinical Global Impression Scale – Severity (CGI-S).[6 months post stabilisation period. <br>Upon enrolment, patients start a 3-month stabilisation period, prior to the study period of 6 months.]